BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 19821328)

  • 1. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WITHDRAWN: Ovarian ablation for early breast cancer.
    Clarke MJ
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000485. PubMed ID: 18843610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN: Tamoxifen for early breast cancer.
    Clarke MJ
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000486. PubMed ID: 18843611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
    Figg WD; Cook K; Clarke R
    Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
    Clarke MJ
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000487. PubMed ID: 18843612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
    Burstein HJ; Prestrud AA; Seidenfeld J; Anderson H; Buchholz TA; Davidson NE; Gelmon KE; Giordano SH; Hudis CA; Malin J; Mamounas EP; Rowden D; Solky AJ; Sowers MR; Stearns V; Winer EP; Somerfield MR; Griggs JJ;
    J Clin Oncol; 2010 Aug; 28(23):3784-96. PubMed ID: 20625130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latent class joint model of ovarian function suppression and DFS for premenopausal breast cancer patients.
    Zhang JJ; Wang M
    Stat Med; 2010 Sep; 29(22):2310-24. PubMed ID: 20552577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
    Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
    J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
    Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
    Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives.
    Love RR
    Oncology (Williston Park); 2010 Apr; 24(4):322-7. PubMed ID: 20464842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    ;
    Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Regan MM; Walley BA; Francis PA; Fleming GF; Láng I; Gómez HL; Colleoni M; Tondini C; Pinotti G; Salim M; Spazzapan S; Parmar V; Ruhstaller T; Abdi EA; Gelber RD; Coates AS; Goldhirsch A; Pagani O
    Ann Oncol; 2017 Sep; 28(9):2225-2232. PubMed ID: 28911092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
    Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
    Lambertini M; Moore HCF; Leonard RCF; Loibl S; Munster P; Bruzzone M; Boni L; Unger JM; Anderson RA; Mehta K; Minton S; Poggio F; Albain KS; Adamson DJA; Gerber B; Cripps A; Bertelli G; Seiler S; Ceppi M; Partridge AH; Del Mastro L
    J Clin Oncol; 2018 Jul; 36(19):1981-1990. PubMed ID: 29718793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Mar; 3(3):CD004706. PubMed ID: 22419298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
    Petersen SH; Harling H; Kirkeby LT; Wille-Jørgensen P; Mocellin S
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD004078. PubMed ID: 22419291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
    Pagani O; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Goetz MP; Ciruelos EM; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Chini C; Puglisi F; Spazzapan S; Ruhstaller T; Winer EP; Ruepp B; Loi S; Coates AS; Gelber RD; Goldhirsch A; Regan MM; Francis PA;
    J Clin Oncol; 2023 Mar; 41(7):1376-1382. PubMed ID: 36521078
    [No Abstract]   [Full Text] [Related]  

  • 18. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    Johansson A; Dar H; van 't Veer LJ; Tobin NP; Perez-Tenorio G; Nordenskjöld A; Johansson U; Hartman J; Skoog L; Yau C; Benz CC; Esserman LJ; Stål O; Nordenskjöld B; Fornander T; Lindström LS
    J Clin Oncol; 2022 Dec; 40(35):4071-4082. PubMed ID: 35862873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
    Sa-Nguanraksa D; Krisorakun T; Pongthong W; O-Charoenrat P
    Mol Clin Oncol; 2019 Nov; 11(5):517-522. PubMed ID: 31620283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
    van Hellemond IEG; Geurts SME; Tjan-Heijnen VCG
    Curr Treat Options Oncol; 2018 Apr; 19(5):26. PubMed ID: 29704066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.